ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.
December 7, 2019 – ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)
November 14, 2019 – ALX Oncology to Present ALX148 Clinical Data at the 61st American Society of Hematology Annual Meeting (ASH)